A Phase 2 interventional study of REGN7999 and Placebo in Non-Transfusion Dependent Beta-Thalassemia (NTDT), sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 26 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is.
The study is looking at several other research questions, including:
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
This study's enrollment of 19 is below the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Browse beta-Thalassemia studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized 2:2:1
Drug: REGN7999
Randomized 2:2:1
Drug: REGN7999
Randomized 2:2:1
Drug: Placebo
Randomized 2:2:1
Drug: REGN7999
Randomized 2:2:1
Drug: REGN7999
Randomized 2:2:1
Drug: Placebo
Administered subcutaneous (SC)
Administered SC
Change from baseline in Liver Iron Concentration (LIC) by R2* Magnetic Resonance Imaging (MRI)
Time frame: At week 24
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to week 72
Severity of TEAEs
Time frame: Up to week 72
Achievement of ≥20% reduction from baseline in LIC by R2* MRI
Time frame: Through week 52
Change from baseline in hemoglobin
Time frame: To week 24
Change from baseline in LIC by R2* MRI
Time frame: At week 52
Percent change from baseline in LIC by R2* MRI
Time frame: To week 24 and week 52
Achievement of ≥20% reduction from baseline in LIC by R2* MRI
Time frame: Through week 24
Change in hemoglobin over time
Time frame: Up to week 56
Achievement of ≥1.5 g/dL increase in hemoglobin for two consecutive assessments in the absence of Red Blood Cell (RBC) transfusions
Time frame: Baseline to week 56
Number of RBC transfusions required
Time frame: Baseline to week 72
Achievement of transfusion independence
Time frame: Baseline to week 72
Change in RBC counts over time
Time frame: Baseline to week 56
Concentrations of REGN7999 in serum over time
Time frame: Up to week 56
Incidence of Anti-Drug Antibody (ADA) to REGN7999 over time
Time frame: Up to week 56
Magnitude of ADA to REGN7999 over time
Time frame: Up to week 56
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Of 29 phase 2 interventional studies under beta-Thalassemia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's planned 26 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.